The FDA approved tebentafusp-tebn (Kimmtrak, Immunocore), a bispecific T-cell engager (BiTE) designed to redirect the immune system to recognize and kill cancerous cells, for the treatment of adults with unresectable or metastatic uveal melanoma.
Tebentafusp-tebn is the first T-cell receptor (TCR) therapeutic to receive regulatory approval from the FDA and the first BiTE approved to treat a solid tumor, Immunocore said in a press release. It also is the only therapy approved to treat this rare